A site where you can find recommended contractors for non-clinical testing｜effical " Non-Clinical CROs and Agencies " Alira Health

Alira Health

Table of Contents

Alira Health is a company that supports the entire product lifecycle, from early development of pharmaceuticals and medical devices to clinical trials, regulatory submissions, and market access. The company has particular strengths in CMC (Chemistry, Manufacturing, and Controls) and regulatory strategy, and comprehensively supports companies' development strategies with a patient-centric approach. This page summarizes Alira Health's features and strengths based on our research.

Non-clinical studies undertaken by Alira Health

Design and strategize non-clinical studies

for a Proof of Concept (PoC) toward a new drug candidate,Support for non-clinical study budget planning, design, and schedule development.We will build a strategic approach to pharmacological and toxicological studies based on the requirements of regulatory authorities such as the FDA and EMA, and reduce development risks by providing a roadmap for a smooth transition to subsequent clinical trials.

Selection of External CRO/CDMO

Since Alira Health does not have a laboratory,Selection of external CDMOs and GLP-compliant CROs suitable for customer needs and development itemsWe will support contract negotiations for master service agreements, provide technical oversight, and manage quality control on behalf of clients, working to ensure that non-clinical trials outsourced to external vendors proceed on schedule.

Regulatory Affairs and CMC support

Instead of completing the planning and execution of non-clinical studies independently, we collaborate with CMC (Chemistry, Manufacturing, and Controls) and regulatory strategy. We oversee the manufacturing of toxicological study lots used in non-clinical studies, and support the development and qualification of analytical methods. The data obtained from study execution,To consistently assist with the creation of application materials for submission to regulatory authorities.The company is doing so.

Alira Health's Contracted Company Introduction

The official website did not contain information regarding specific external contract research organizations (CROs) or contract development and manufacturing organizations (CDMOs) that Alira Health partners with or handles.

Alira Health's Nonclinical Trial Case Studies

Alira Health's preclinical trial cases were not posted on the official website.

Alira Health Company Information

Address	1 Grant Street, Suite 400, Framingham, MA 01702, USA
Tel	+1-774-777-5255
Website	https://alirahealth.com

3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation

SMC Laboratories, Inc.

Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)

SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.

Consult study design and disease model development
with SMC Laboratories, Inc.

Consult SMC Laboratories
Call us

Safety Studies
Comprehensive Safety Evaluation for FIH Applications

Labcorp Holdings Inc.
(Labcorp Drug Development)

Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)

Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.

Consult Labcorp Holdings Inc.
Discuss GLP/ICH-compliant study design for your FIH submission.

To labcorp.
Call us

Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation

PhoenixBio Co., Ltd.

Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)

PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

Consult Phoenix Bio for PK/PD analysis with a clinical focus

Phoenix Bio.
Call us